AF
FOLD

Amalgamated Financial’s Amicus Therapeutics FOLD Stock Holding History

Amalgamated Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$408K Buy
+43,048
New +$404K ﹤0.01% 1608

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's FOLD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Amicus Therapeutics (FOLD) in Q1 2022: 43,048 shares worth $408K. The stake represents ﹤0.01% of the portfolio and ranks #1608 among its holdings.

217 funds tracked by Wall St. Rank hold FOLD as of Q1 2022.

  • Amalgamated Financial held 43,048 shares of Amicus Therapeutics worth $408K as of Q1 2022.
  • Amicus Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Amicus Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1608 holding.
  • 217 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.